Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
| Status: | Completed |
|---|---|
| Conditions: | Pneumonia, Hospital |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/18/2019 |
| Start Date: | February 2005 |
| End Date: | July 2007 |
A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus
Study 0015 (NCT00107952) compares the safety and effectiveness of an investigational drug,
telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
Inclusion Criteria:
- Clinical signs and symptoms consistent with pneumonia acquired after at least 48 hours
of continuous stay in an inpatient acute or chronic care facility or acquired within 7
days after being discharged from a hospitalization of greater than or equal to 3 days
duration.
Exclusion Criteria:
- Received more than 24 hours of potentially effective systemic (IV, IM or PO)
antibiotic therapy for Gram-positive pneumonia immediately prior to randomization
We found this trial at
1
site
Baystate Medical Center Baystate Medical Center (BMC), in Springfield, Massachusetts, is an academic, research, and...
Click here to add this to my saved trials
